Platelet-activating factor acetylhydrolases: An overview and update

被引:33
作者
Kono, Nozomu [1 ,2 ]
Arai, Hiroyuki [1 ,3 ]
机构
[1] Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Chem, Bunkyo Ku, Tokyo 1130033, Japan
[2] Japan Agcy Med Res & Dev, PRIME, Chiyoda Ku, 1-7-1 Otemachi, Tokyo 1000004, Japan
[3] Japan Agcy Med Res & Dev, AMED CREST, Chiyoda Ku, 1-7-1 Otemachi, Tokyo 1000004, Japan
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS | 2019年 / 1864卷 / 06期
基金
日本学术振兴会;
关键词
Platelet-activating factor; Oxidized phospholipids; PAF-AH; CORONARY-ARTERY-DISEASE; C-REACTIVE PROTEIN; MIDDLE-AGED MEN; FUTURE CARDIOVASCULAR EVENTS; FACTOR PAF ACETYLHYDROLASE; DIEKER LISSENCEPHALY GENE; PHOSPHOLIPASE A(2); RISK-FACTOR; OXIDIZED PHOSPHOLIPIDS; CATALYTIC SUBUNITS;
D O I
10.1016/j.bbalip.2018.07.006
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Platelet-activating factor acetylhydrolases (PAF-AHs) are unique members of the phospholipase A(2 )family that can hydrolyze the acetyl group of PAF, a signaling phospholipid that has roles in diverse (patho)physiological processes. Three types of PAF-AH have been identified in mammals, one plasma type and two intracellular types [PAF-AH (I) and PAF-AH (II)]. Plasma PAF-AH and PAF-AH (II) are monomeric enzymes that are structurally similar, while PAF-AH (I) is a multimeric enzyme with no homology to other PAF-AHs. PAF-AH (I) shows a strong preference for an acetyl group, whereas plasma PAF-AH and PAF-AH (II) also hydrolyze phospholipids with oxidatively modified fatty acids. Plasma PAF-AH has been implicated in several diseases including cardiovascular disease. PAF-AH (I) is required for spermatogenesis and is increasingly recognized as an oncogenic factor. PAF-AH (II) was recently shown to act as a bioactive lipid-producing enzyme in mast cells and thus could be a drug target for allergic diseases. This article is part of a Special Issue entitled Novel functions of phospholipase A2 Guest Editors: Makoto Murakami and Gerard Lambeau.
引用
收藏
页码:922 / 931
页数:10
相关论文
共 128 条
[11]   A prospective evaluation of lipoprotein-associated phospholipase A2 levels and the risk of future cardiovascular events in women [J].
Blake, GJ ;
Dada, N ;
Fox, JC ;
Manson, JE ;
Ridker, PM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 38 (05) :1302-1306
[12]   Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis [J].
Blankenberg, S ;
Stengel, D ;
Rupprecht, HJ ;
Bickel, C ;
Meyer, J ;
Cambien, F ;
Tiret, L ;
Ninio, E .
JOURNAL OF LIPID RESEARCH, 2003, 44 (07) :1381-1386
[13]   Generation and Biological Activities of Oxidized Phospholipids [J].
Bochkov, Valery N. ;
Oskolkova, Olga V. ;
Birukov, Konstantin G. ;
Levonen, Anna-Liisa ;
Binder, Christoph J. ;
Stoeckl, Johannes .
ANTIOXIDANTS & REDOX SIGNALING, 2010, 12 (08) :1009-1059
[14]   Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up [J].
Brilakis, ES ;
McConnell, JP ;
Lennon, RJ ;
Elesber, AA ;
Meyer, JG ;
Berger, PB .
EUROPEAN HEART JOURNAL, 2005, 26 (02) :137-144
[15]   Intensive versus moderate lipid lowering with statins after acute coronary syndromes [J].
Cannon, CP ;
Braunwald, E ;
McCabe, CH ;
Rader, DJ ;
Rouleau, JL ;
Belder, R ;
Joyal, SV ;
Hill, KA ;
Pfeffer, MA ;
Skene, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) :1495-1504
[16]   Lipoprotein-Associated Phospholipase A2 Interacts with Phospholipid Vesicles via a Surface-Disposed Hydrophobic α-Helix [J].
Cao, Jian ;
Hsu, Yuan-Hao ;
Li, Sheng ;
Woods, Virgil L., Jr. ;
Dennis, Edward A. .
BIOCHEMISTRY, 2011, 50 (23) :5314-5321
[17]   Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase:: a potential new risk factor for coronary artery disease [J].
Caslake, MJ ;
Packard, CJ ;
Suckling, KE ;
Holmes, SD ;
Chamberlain, P ;
Macphee, CH .
ATHEROSCLEROSIS, 2000, 150 (02) :413-419
[18]   Lipoprotein-associated phospholipase A2, inflammatory biomarkers, and risk of cardiovascular disease in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) [J].
Caslake, Muriel J. ;
Packard, Chris J. ;
Robertson, Michele ;
Cooney, Josephine ;
Nelson, Jeanenne J. ;
Ford, Ian ;
Gaw, Allan ;
Jukema, J. Wouter ;
Macfarlane, Peter W. ;
Stott, David J. ;
Shepherd, James .
ATHEROSCLEROSIS, 2010, 210 (01) :28-34
[19]   Selective Inhibitor of Platelet-Activating Factor Acetylhydrolases 1b2 and 1b3 That Impairs Cancer Cell Survival [J].
Chang, Jae Won ;
Zuhl, Andrea M. ;
Speers, Anna E. ;
Niessen, Sherry ;
Brown, Steven J. ;
Mulvihill, Melinda M. ;
Fan, Yi Chiao ;
Spicer, Timothy P. ;
Southern, Mark ;
Scampavia, Louis ;
Fernandez-Vega, Virneliz ;
Dix, Melissa M. ;
Cameron, Michael D. ;
Hodder, Peter S. ;
Rosen, Hugh ;
Nomura, Daniel. K. ;
Kwon, Ohyun ;
Hsu, Ku-Lung ;
Cravatt, Benjamin F. .
ACS CHEMICAL BIOLOGY, 2015, 10 (04) :925-932
[20]   The Role of Lipoprotein-Associated Phospholipase A2 in a Murine Model of Experimental Autoimmune Uveoretinitis [J].
Crawford, G. L. ;
Boldison, J. ;
Copland, D. A. ;
Adamson, P. ;
Gale, D. ;
Brandt, M. ;
Nicholson, L. B. ;
Dick, A. D. .
PLOS ONE, 2015, 10 (04)